CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
We are pleased to inform you that the Canadian Cancer Trials Group (CCTG) is organizing our next Clinical Research Associate (CRA) Lunch and Learn training program, to be held on Wednesday, May 13th, 2026, at 12 pm ET on the topic: NCTN Clinical Trial Support Unit (CTSU) OPEN System and upcoming changes
Congratulations to the IND241 trial team at Princess Margaret Cancer Centre who were awarded the CCTG IND Team Award at the Annual Spring Meeting this past weekend. The team members include, David Cescon (QI), Julia Wang, Soha Ahrari, Irene Li, Simi Malhotra, Lindsay Muyot, Helia Purnaghshband, Carolina Sanabria Salas, Maria Ye, Divyalakshmi Babu, Jennifer Bornstein, Christine Cater, Julia D'Souza, Shirley Ho, Ansu Jomy Jose, Sul Hee Kim, Irum Mahmood, Alexis Maneja, Karla Moreira, Sam (sang pil) Park, and Rosa Pezzulli
CCTG presented Dr. Erica Tsang from Princess Margaret Cancer Centre the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award to recognize her work as a new investigator who has worked on IND projects and contributed significantly to the conduct of an IND trial at a member centre.
The MA40 trial, a double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor has closed to further accrual as the accrual target of 250 study participants enrolled.
Please join the Patient Representative Committee in welcoming Michelle Audoin who will be supporting the Breast Disease Site committee.
At the recent annual meeting of the Austrian Working Group for Gynaecological Oncology in the Austrian Society for Gynecology and Obstetrics the Ernst Wertheim Award was presented to Dr Marie Plante, the CCTG CX5 study lead and Gynecologic Oncologist at CHU de Quebec, Canada.
